Kawahata I - Search Results

1

Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects.

Wilar G, Suhandi C, Wathoni N, Fukunaga K, Kawahata I. Wilar G, et al. Among authors: kawahata i. Int J Nanomedicine. 2024 Nov 6;19:11357-11378. doi: 10.2147/IJN.S484838. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39524925 Free PMC article. Review.

2

Advances in Blood Biomarkers and Diagnosis Approaches for Neurodegenerative Dementias and Related Diseases.

Sekimori T, Fukunaga K, Finkelstein DI, Kawahata I. Sekimori T, et al. Among authors: kawahata i. J Integr Neurosci. 2024 Oct 10;23(10):188. doi: 10.31083/j.jin2310188. J Integr Neurosci. 2024. PMID: 39473150 Free article. Review.

3

Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis.

Wilar G, Suhandi C, Fukunaga K, Kawahata I. Wilar G, et al. Among authors: kawahata i. Heliyon. 2024 Sep 20;10(19):e38229. doi: 10.1016/j.heliyon.2024.e38229. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39381111 Free PMC article.

4

FABP2 is Involved in Intestinal α-Synuclein Pathologies.

Sekimori T, Fukunaga K, Oizumi H, Baba T, Totsune T, Takeda A, Sasaki T, Kawahata I. Sekimori T, et al. Among authors: kawahata i. J Integr Neurosci. 2024 Feb 22;23(2):44. doi: 10.31083/j.jin2302044. J Integr Neurosci. 2024. PMID: 38419457 Free article.

5

[Development of early prediction and discriminating techniques for Lewy body diseases].

Kawahata I, Takeda A, Fukunaga K. Kawahata I, et al. Nihon Yakurigaku Zasshi. 2024;159(1):2-5. doi: 10.1254/fpj.23065. Nihon Yakurigaku Zasshi. 2024. PMID: 38171833 Japanese.

6

[Preface].

Kawahata I, Nagai M. Kawahata I, et al. Nihon Yakurigaku Zasshi. 2024;159(1):1. doi: 10.1254/fpj.23099. Nihon Yakurigaku Zasshi. 2024. PMID: 38171829 Japanese. No abstract available.

7

Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson's Disease-Potential Biomarkers and Therapeutic Targets.

Kawahata I, Fukunaga K. Kawahata I, et al. Int J Mol Sci. 2023 Dec 1;24(23):17037. doi: 10.3390/ijms242317037. Int J Mol Sci. 2023. PMID: 38069360 Free PMC article. Review.

8

Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson's Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique.

Kawahata I, Sekimori T, Oizumi H, Takeda A, Fukunaga K. Kawahata I, et al. Int J Mol Sci. 2023 Aug 26;24(17):13267. doi: 10.3390/ijms241713267. Int J Mol Sci. 2023. PMID: 37686075 Free PMC article.

9

Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model.

Cheng A, Jia W, Finkelstein DI, Stefanova N, Wang H, Sasaki T, Kawahata I, Fukunaga K. Cheng A, et al. Among authors: kawahata i. Acta Pharmacol Sin. 2024 Jan;45(1):66-75. doi: 10.1038/s41401-023-01138-y. Epub 2023 Aug 21. Acta Pharmacol Sin. 2024. PMID: 37605049

10

Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation.

Cheng A, Kawahata I, Wang Y, Jia W, Wang H, Sekimori T, Chen Y, Suzuki H, Takeda A, Stefanova N, Finkelstein DI, Ma W, Chen M, Sasaki T, Fukunaga K. Cheng A, et al. Among authors: kawahata i. Brain. 2023 Aug 1;146(8):3172-3180. doi: 10.1093/brain/awad137. Brain. 2023. PMID: 37082980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters